Palliative Short-course Hypofractionated Radiotherapy Followed by Chemotherapy in Adenocarcinoma of the Esophagus or Esophagogastric Junction Trial - a Phase II Clinical Trial Protocol.

Inclusion Criteria: * Patients with histologically proven adenocarcinoma of the esophagus or esophagogastric junction noneligible for surgery or chemoradiation with curative intent * Any T, N and M * Age: 18 years or older * WHO performance status ≤ 2 * Life expectancy \> 3 months * Dysphagia score \> 0 * Adequate laboratory findings: hemoglobin \> 90 g/L, absolute neutrophil count * 1.0 10 9/L, platelets ≥ 75 x 10 9/L, bilirubin ≤ 1.5 x upper limit of normal (ULN), alanine aminotransferase (ALAT) ≤ 5 x ULN, creatinine ≤ 1.5 x ULN * Fertile men and women must use effective means of contraception * Signed written informed concent * The patient must be able to comply with the protocol Exclusion Criteria: * Prior treatment with self-expanding metal stent (SEMS), radiotherapy or chemotherapy for the present disease * Clinically significant (i.e. active) cardiovascular disease e.g. myocardial infarction (≤ 6 months) unstable angina, New York Heart Association (NYHA) grade III-IV congestive heart failure * Severe pulmonary disease e.g. pulmonary fibrosis * Symptomatic peripheral neuropathy greater than grade 1 (CTCAE v. 4.0) * Known hypersensitivity to any contents of the study drugs * Pregnancy ( positive pregnancy test) and/or breast feeding * Any other serious or uncontrolled illness which in the opinion of the investigator makes it undesirable for the patient to enter the trial